ASCO 2013: Highlights in Chronic Myelogenous Leukemia


Recently Approved Drugs for CML, Their Safety and Efficacy Data, and How They Are Currently Approved to Be Used Within the Treatment Continuum
Jorge Eduardo Cortes, MD

Begin


Nilotinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Stuart L. Goldberg, MD

Begin


Economic Benefits of Adequate Molecular Monitoring in Patients with CML
Stuart L. Goldberg, MD

Begin


Overcoming Resistance in Chronic Myelogenous Leukemia
Michael J. Mauro, MD

Begin

FDA Safety Alert
UPDATED 12/20/2013. Ponatinib has been reinstated by the US FDA with update to the labeling and a REMS program. Read More Here U.S. Resumption of Marketing and Commercial Distribution of Ponatinib in Refractory Philadelphia-Positive Leukemias